Suntrust Banks’s Sonnet BioTherapeutics SONN Stock Holding History

Suntrust Banks’s Portfolio SONN Stock Details SONN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$27K	Buy	+1	New	+$45.8K	﹤0.01%	1318

Other funds holding SONN

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

QCIG

Quad-Cities Investment Group Davenport, Iowa $278M AUM 22.38% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Suntrust Banks's SONN Position: Q3 2019 in Review

Suntrust Banks opened a new position in Sonnet BioTherapeutics (SONN) in Q3 2019: 1 share worth $27K. The stake represents ﹤0.01% of the portfolio and ranks #1318 among its holdings.

2 funds tracked by Wall St. Rank hold SONN as of Q3 2019.

Suntrust Banks held 1 share of Sonnet BioTherapeutics worth $27K as of Q3 2019.
Sonnet BioTherapeutics was a new Suntrust Banks position in Q3 2019.
Sonnet BioTherapeutics made up ﹤0.01% of Suntrust Banks's portfolio in Q3 2019, its #1318 holding.
2 funds tracked by Wall St. Rank held Sonnet BioTherapeutics as of Q3 2019.

Based on Suntrust Banks's 13F filing for Q3 2019, filed 12 Nov 2019.